Get started
Author

Gonzalo Gomez-Abuin

Observed names: G. Gomez-Abuin, Gomez-Abuin Gonzalo
Institution: Hospital Alemán
ORCID: 0009-0002-1414-848X
Observed ORCID: 0009-0002-1414-848X
OpenAlex ID: A5020180074
Pharmacokinetic variability of anticancer agents
2005 · Samir D. Undevia, Gonzalo Gomez-Abuin, et al. · Nature reviews. Cancer · 259
Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model
2004 · Radan Dzodic, Gonzalo Gomez-Abuin, et al. · Anti-Cancer Drugs · 99
Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases
2005 · L. Albiges, F. André, et al. · Annals of Oncology · 94
PDF
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia
2006 · Gonzalo Gomez-Abuin, Eric Winquist, et al. · Investigational New Drugs · 34
Acalculous Cholecystitis in a Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib
2009 · Gonzalo Gomez-Abuin, Aída Amelia Karam, et al. · Clinical Genitourinary Cancer · 32
Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomas
2011 · Ruiz-Soto Rodrigo, Auger Nathalie, et al. · European Journal of Cancer · 25
Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck
2011 · V.M. Villaflor, D. Haraf, et al. · Annals of Oncology · 20
Main challenges to cancer care in Latin America: an analysis through breast cancer lenses
2025 · Gonzalo Gomez-Abuin, Pablo Mandó, et al. · The Lancet Regional Health - Americas · 15
PDF
pionERA Breast Cancer (BC): Phase III study of first-line (1L) giredestrant vs. fulvestrant, both combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), in patients (pts) with estrogen receptor-positive (ER+), HER2– locally advanced/metastatic BC (LA/mBC) with resistance to prior adjuvant (adj) endocrine therapy (ET).
2024 · Kevin Kalinsky, Rinath Jeselsohn, et al. · Journal of Clinical Oncology · 5
442P Menopausal status may derive in different second-line treatment benefits in breast cancer patients that experienced disease progression with CDK4/6 inhibitors (SUMA-001)
2023 · F.D. Waisberg, P. Mando, et al. · Annals of Oncology · 3
PDF
Phase II trial pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated head and neck cancer patients
2008 · V. M. Villaflor, E. E. Cohen, et al. · Journal of Clinical Oncology · 2
283P Immune-mediated secondary adrenal insufficiency is more commonly found in younger patients undergoing neoadjuvant treatment for early breast cancer
2024 · L.S. Lapuchesky, F.D. Waisberg, et al. · Annals of Oncology · 1
PDF
123P Biomarker testing in hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer (mBC): Expert recommendations
2025 · T. Reinert, A.S. El Shehri, et al. · Annals of Oncology
601P Characterizing the patient subgroup with short first-line (1L-PFS) and long second-line progression free survival (2L-PFS) in an Argentinean multicentric HR+/HER2- metastatic breast cancer cohort
2025 · F.D. Waisberg, P. Mando, et al. · Annals of Oncology
Abstract P4-08-01: pionERA Breast Cancer: Phase 3 study of first-line giredestrant vs fulvestrant, + a CDK4/6 inhibitor, in patients with estrogen receptor+, HER2- locally advanced/metastatic breast cancer with resistance to prior adjuvant endocrine therapy
2025 · Kevin Kalinsky, Rinath Jeselsohn, et al. · Clinical Cancer Research
82P Unveiling patterns of genomic testing in HR+/HER2- early breast cancer in a resource-limited setting: Are we closing the gap?
2025 · V.M. Lopez, S.G. Rivero, et al. · ESMO Open
PDF
Determining Clinicopathologic Factors That Influence Treatment in Advanced Breast Cancer in Argentina After CDK4/6 Inhibitors
2024 · Federico Waisberg, Pablo Mandó, et al. · JCO Global Oncology
PDF
Effect of age on completion of intraperitoneal chemotherapy in ovarian cancer
2016 · M. Tamburelli, M.V. Bluthgen, et al. · Annals of Oncology
PDF
Causes of discontinuation of intraperitoneal chemotherapy in patients with ovarian cancer.
2012 · Mercedes Tamburelli, Gabriela Gatica, et al. · Journal of Clinical Oncology
Works count: 19
Citation count: 589
H-index: 8
I10-index: 8
Year
Topic
Type